– USA, CA – Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company today announced the appointment of Brenda Becker to its Board of Directors, effective March 15, 2022.
Ms. Becker has also joined the Nominating and Governance Committee.
About Brenda Becker
Brenda Becker has more than 40 years of combined private and public sector experience focused on health policy and legislation. She currently serves as SVP, Global Government Affairs at Boston Scientific.
Before joining Boston Scientific in 2007, Ms. Becker served in the George W. Bush administration under former VP Dick Cheney as Assistant to VP for Legislative Affairs. In that capacity, she advised VP and senior White House staff on legislative strategy from 2004 to 2007. In addition, Ms. Becker was nominated by President Bush and confirmed by the U.S. Senate in 2001 to serve as the Assistant Secretary for Legislative and Intergovernmental Affairs at the U.S. Department of Commerce where she provided counsel to the Secretary of Commerce and other senior commerce officials. Before entering public service, Ms. Becker held increasing roles of responsibility overseeing state and federal affairs at the Blue Cross Blue Shield Association for 20 years.
“I share Sight Sciences’ belief that innovation in eyecare products has the potential to improve patients’ vision and their quality of life,” said Ms. Becker. “It’s an honor to join Sight Sciences’ Board of Directors. I look forward to contributing toward its next stages of growth as they expand their existing businesses in glaucoma and dry eye and develop their robust pipeline of innovations in ophthalmology and optometry.”
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI Surgical System is a minimally invasive glaucoma surgery device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, the world’s leading cause of irreversible blindness. The Company’s TearCare System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction, enabling office-based clearance of gland obstructions by an eye care professional to address the leading cause of dry eye disease.
For more information: https://www.sightsciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
